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Abstract 
Background: Systemic inflammation is an important risk factor for neurodevelopmental impairments in preterm 
infants. Premyelinating oligodendrocytes are main building blocks of white matter in preterm infants and vulnerable 
to oxidative stress and excitotoxic stress. Tumour necrosis factor‑α (TNF‑α) plays important roles in systemic inflamma‑
tion and local inflammation leading to apoptosis of premyelinating oligodendrocytes and white matter injury (WMI) 
in brain tissue. This study was conducted to investigate whether etanercept, a TNF‑α antagonist, could attenuate 
systemic lipopolysaccharide (LPS)‑induced WMI in the immature brain.
Results: We found that intraperitoneal LPS administration caused systemic and local inflammation in brain tissue. 
Subsequent etanercept treatment significantly attenuated LPS‑induced inflammation in brain tissue as well as in 
systemic circulation. Intraperitoneal LPS also induced microgliosis and astrocytosis in the cingulum and etanercept 
treatment reduced LPS‑induced microgliosis and astrocytosis. Additionally, systemic LPS‑induced apoptosis of oligo‑
dendrocyte precursor cells was observed, which was lessened by etanercept treatment. The concentration of etaner‑
cept in the CSF was higher when it was administrated with LPS than when administrated with a vehicle.
Conclusions: It appears that etanercept reduce WMI in the neonatal rat brain via attenuation of systemic and local 
inflammation. This study provides preclinical data suggesting etanercept‑mediated modulation of inflammation as a 
promising approach to reduce WMI caused by sepsis or necrotizing enterocolitis in preterm infants.
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Background
During the neonatal period, preterm infants are at risk 
from several morbidities, such as sepsis and necrotiz-
ing enterocolitis, that are associated with neurodevelop-
ment impairments [1, 2], which have been shown to be 
mediated by white matter injury (WMI) in the premature 
brain [2, 3]. The pathogenesis of WMI is characterised 
by a loss of premyelinating oligodendrocytes (pre-OLs), 
which are particularly vulnerable to oxidative and excito-
toxic stress, and activation of glial cells, such as microglia 
and astrocytes [4, 5].
Several pro-inflammatory cytokines are associated with 
the activation of glial cells [6]. Post-mortem brain speci-
mens from infants with periventricular WMI exhibited 
the expression of various cytokines, including tumour 
necrosis factor-α (TNF-α), during the early stages of 
white matter disease [7]. The roll of TNF-α in WMI has 
been reported in several studies. TNF-α mediated the 
lipopolysaccharide (LPS)-triggered death of pre-OLs 
in an environment containing major glial cell types [8], 
and oligodendrocyte progenitors were particularly vul-
nerable to a combination of TNF-α and interferon-γ by 
activation of the cell death program [9]. However, most of 
studies which reported roll of glial cells and TNF-α in the 
death of oligodendrocytes during the early developmen-
tal phase used in  vitro methods with direct stimulation 
with LPS [8, 10, 11]. Etanercept is a TNF-α antagonist 
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composed of the dimeric fusion protein of the extracel-
lular ligand-binding portion of the soluble 75-kDa TNF-α 
receptor II and the fragment-crystallisable (Fc) portion 
of human immunoglobulin (IgG) [12]. Recently, etaner-
cept has been shown to attenuate neural apoptosis, astro-
cytic and microglial activation, and local inflammation of 
the brain in several animal studies using traumatic brain 
injury or ischaemic injury models [13, 14]. In a study of a 
traumatic brain injury model, injection of intraperitoneal 
etanercept of 5  mg/kg reduced neuronal degeneration 
after 1 h, and in a study involving a rat ischemic stroke 
model, etanercept given intraperitoneally 30  min after 
insult decreased cerebral infarct [14, 15]. The present 
study was conducted to establish a neonatal rat model of 
WMI corresponding to WMI in human preterm infants 
by inducing systemic inflammation. Furthermore, we 
hypothesized that administration of TNF-α antagonist 
following LPS-induced systemic inflammation could 
attenuate apoptosis of pre-OLs in the inflamed immature 
brain of newborn rats with subsequent preservation of 
myelination in the cingulum.
Results
All rats survived until experimental sacrifice. Compared 
with the P group, rats in both the L and LE groups expe-
rienced a slight decrease in body weight on P4 (Fig.  1). 
Despite the subsequent increase, the body weight of the 
L group was significantly lower than that of the P group 
from P5 to P7, and rats in the LE group showed no sig-
nificant differences in weight during P5 and P7 compared 
with the P group.
LPS‑induced inflammatory responses were attenuated 
by etanercept
Systemic exposure to LPS resulted in inflammatory 
responses in the brain and serum on P4 (Fig.  2a, IL-1ß 
and Fig. 2b, TNF-α). Serum IL-1ß and TNF-α concentra-
tions were increased in LPS-exposed rats compared with 
the placebo rats, and the levels in the brain tissue were 
also significantly increased in LPS-exposed rats. The LE 
group showed lower IL-1ß levels in serum and lower 
TNF-α levels in serum and brain tissue than the L group, 
but attenuation of IL-1ß in the brain was not significant 
in the LE group.
Etanercept preserved premyelinating oligodendrocytes 
during LPS exposure
LPS exposure resulted in decreased PDGFα-R and 
NG2 immunostaining in the brain tissue on P4 (Fig. 3a, 
b, d, e, p, q), but these were significantly increased in 
the LE group compared to the L group (Fig. 3c, f, p, q). 
Decreased distribution of pre-OLs in the LPS-exposed 
rat brains was also evidenced by decreased O4 immu-
nofluorescence staining, and the O4+ cell was increased 
in the LE group compared to the L group (Fig. 3g–i, r). 
TUNEL immunofluorescence staining also was increased 
in the L group on P4, and this increase was attenuated 
Fig. 1 Etanercept‑attenuated poor body weight gain in LPS‑treated 
rats. **Represents a significant difference between groups (P < 0.01)
Fig. 2 The LPS‑induced changes in the levels of inflammatory 
cytokines in circulation and the brain tissue of rats on P4 (a IL‑1ß and 
b TNF‑α). ** and *represent significant differences between groups 
(P < 0.01 and P < 0.05, respectively). ANOVA with a Bonferroni test was 
conducted. There were six rats per group
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Fig. 3 Representative photomicrographs of pre‑OLs a–f by immunohistochemistry using PDGFα‑R and NG2 and O4+ oligodendrocyte (g–i) and 
TUNEL staining cells j–l by immunofluorescence (IF) staining of the cingulum (Bregma − 1.0) on P4. Pre‑OLs were attenuated in the L group and 
preserved in the LE group (p, q). Double‑labelling showed that many TUNEL‑positive cells were also positive for O4 (m–o). O4+ oligodendrocytes 
were decreased in the L group with increased TUNEL‑positive cells in the IF staining, and O4+ oligodendrocytes were recovered in the LE group 
(r–t). ** and *represent significant differences between groups (P < 0.01 and P < 0.05, respectively). ANOVA with a Bonferroni test was conducted. 
There were six rats per group
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in the LE group (Fig.  3j–l, s). Double-labelling showed 
that many TUNEL-positive cells were positive for O4 
(Fig.  3n), and the cells that were doubly stained by O4 
and TUNEL were decreased in the LE group (Fig. 3m–o, 
t). Double immunofluorescence staining of TNF-α recep-
tor and IL-1ß receptor with O4 in the L group showed 
that each receptor was well expressed on the O4+ cells 
(Fig. 4).
Etanercept attenuated LPS‑induced microgliosis 
and astrocytosis resulting in improved myelination
A significant increase in the number of reactive astro-
cytes showing hypertrophy of cellular processes was 
found in the LPS-exposed rat brains on P4, and this 
increase was attenuated by etanercept treatment 
(Fig. 5a–c, m). Iba-1 immunostaining was also increased 
in the L group, and this increase was attenuated in the 
LE group (Fig.  5d–f, n). Astrocytosis and microgliosis 
were still more prominent in the LE group than the con-
trol group on P4. Double immunofluorescence labelling 
in the L group showed that GFAP or Iba-1 positive cells 
were expressed with TNF-α (Fig.  5g–l). Immunohisto-
chemistry using MBP and LFB on P14 showed that LPS 
exposure resulted in decreased MBP and LFB and these 
were significantly increased in the LE group compared to 
the L group (Fig. 6).
Etanercept levels in the central nervous system
CSF obtained on P4 was analysed by ELISA to detect 
etanercept, and the concentration was higher in the LEC 
group than in the PC group (Fig. 7).
Discussion
A postnatal newborn rat model of systemic inflammation 
was reproduced from the study by Fan et al., in which LPS 
was administered to rats intraperitoneally on day 5 of life 
[16]. The vulnerability of white matter during systemic 
inflammation has been related to the presence of pre-OLs 
at the gestational age of 24–32 weeks in humans, which 
is equivalent to the same pre-OL phenotype in a new-
born rat [17]. Previous studies have suggested that white 
matter vulnerability at postnatal day 4 in a rat or mouse 
would correspond to that in preterm infants [18, 19]. In 
this study, the WMI model was successfully reproduced 
by IP injection of LPS on P3, and the TNF-α antagonist 
etanercept attenuated the LPS-induced inflammatory 
processes with subsequent improvement in myelination.
There was significant systemic inflammation after LPS 
administration in the newborn rats, which subsequently 
exhibited poor weight gain during the 1st  week of life. 
Systemic inflammation not only induced local inflamma-
tion of the brain but subsequent injury as well, as indi-
cated by increased TUNEL-positive cells in the cingulum 
Fig. 4 Representative photomicrographs of O4+ oligodendrocyte (a, d), TNF‑α receptor (b) and IL‑1ß receptor (e) immunofluorescence staining 
of the cingulum (Bregma − 1.0) on P4. Double‑labelling showed that many O4+ oligodendrocyte also were positive for TNF‑α receptors and IL‑1ß 
receptors (c, f)
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white matter. Apoptosis occurred in the O4-positive pre-
OLs with decreased myelination in the white matter and 
was accompanied by microgliosis and astrocytosis in the 
cingulum, which was consistent with the study by Fan 
et  al. [16]. More immature form of pre-OLs containing 
NG2 and PDGFα-R also were influenced by systemic LPS 
and were preserved by TNFα inhibition in this study.
TNF-α was shown to play a critical role in the patho-
genesis of WMI because TNF-α signalling is required in 
LPS-triggered pre-OL death [8]. Pre-OLs do not undergo 
apoptosis when major glial cell types are absent, which 
emphasises the importance of intercellular communica-
tion in the mechanism of inflammatory pre-OL death. 
Through this communication, activation of microglia 
and astrocytes has detrimental effects on neural precur-
sor cells via released TNF-α [20, 21]. The pathogenesis 
of local brain inflammation during systemic inflamma-
tion has not yet been well elucidated, but both direct and 
indirect pathways of triggering local inflammation have 
been suggested. Circumventricular organs in the brain 
might play important roles in the mediation of systemic 
inflammation and the expression of TNF-α in the brain 
Fig. 5 Representative photomicrographs of astrocytosis (a–c) and microgliosis (d–f) by immunohistochemistry and TNF‑α (g, j), GFAP (h) and 
Iba‑1 (k) by immunofluorescence staining of the cingulum (Bregma − 1.0) on P4. Significant increases in the number of reactive astrocytes and 
microgliosis were observed in the cingulum white matter following neonatal LPS exposure, which was attenuated in the LE group (m, n). In the L 
group, GFAP or Iba‑1 positive cells were also positive for TNF‑α (i, l). **Represents significant differences between groups (P < 0.01). ANOVA with a 
Bonferroni test was conducted. There were six rats per group
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with CD14 expression [22]. On the other hand, circulat-
ing TNF-α has the ability to directly activate the endothe-
lium of the brain’s blood vessels, producing soluble 
molecules such as prostaglandins with subsequent local 
inflammation [23]. Many studies used the in vitro meth-
ods with direct stimulation with LPS to demonstrate the 
effect of glial cells and TNF-α on the death of oligoden-
drocytes during the early developmental phase [8, 10, 
11]. In the present study, systemic inflammation by LPS 
in  vivo successfully induced apoptosis of Pre-OLs with 
the expression of receptors for TNF-α and IL-1β on the 
Pre-OLs. These changes were accompanied by increased 
glial cells such as microglia and astrocytes in the brain 
with the expression of TNF-α (Fig. 5).
Etanercept is a TNF-α antagonist that has already been 
developed and approved for the treatment of rheuma-
toid arthritis and several rheumatic diseases, and treat-
ment with etanercept suppressed systemic inflammation 
and local inflammation in the brains of LPS-treated rats. 
It decreased microgliosis and astrocytosis and preserved 
myelination in white matter, subsequently decreasing 
apoptosis of O4-positive pre-OLs in the LPS- and etaner-
cept-treated newborn rats compared to the LPS-exposed 
rats that did not receive etanercept. It is unclear whether 
the effect of etanercept was via suppression of systemic 
inflammation or direct suppression of local inflamma-
tion in the brain or by both mechanisms. However, brain 
TNF-α levels were strongly suppressed in the LE group 
compared to the L group, suggesting a role for etanercept 
Fig. 6 Representative photomicrographs of myelination by immunohistochemistry (a–f). Cells with MBP and LFB staining were attenuated in the 
L group and preserved in the LE group (g, h) of the cingulum (Bregma − 1.0) on P14. ** and *represent significant differences between groups 
(P < 0.01 and P < 0.05, respectively). ANOVA with a Bonferroni test was conducted. There were six rats per group
Fig. 7 ELISA of etanercept levels in the CSF. The concentration of 
etanercept in CSF was higher in the LEC group than in the PC group 
(n = 10 for each group). A t‑test was conducted, and **represents a 
significant difference between groups (P < 0.01)
Page 7 of 9Shin et al. BMC Neurosci           (2019) 20:45 
in modulating local inflammation. Interestingly, etaner-
cept was more detectable with systemic inflammation 
(LEC group) than without (PC group). Etanercept is such 
a large molecule that it is usually unable to penetrate the 
blood–brain barrier (BBB) [24], but the several stud-
ies have demonstrated that the BBB could be disrupted 
by LPS exposure [25, 26]. This functional change in BBB 
during systemic inflammation might widen the therapeu-
tic range in the WMI induced by systemic inflammation 
in preterm infants.
Conclusions
Although preterm infants are at higher risk of conditions 
such as sepsis, meningitis and necrotizing enterocolitis 
during the neonatal period [27], an evidence-based strat-
egy for reducing WMI has not yet been established in this 
population. Clinical studies have accumulated evidence 
of an association between serious postnatal systemic 
inflammation and WMI or neurodevelopmental out-
comes in preterm infants [27, 28]. Therefore, controlling 
undue inflammation in the brain during these episodes 
might help reduce WMI and subsequent neurodevel-
opmental impairment in preterm infants. As TNF-α 
antagonists have already been used to treat a number of 
neurodegenerative and autoimmune diseases, clinical tri-
als would be worthwhile for this potential treatment for 
WMI in preterm infants.
Methods
Animals
Timed pregnant Sprague–Dawley (SD) rats arrived in 
the laboratory on day 19 of gestation. Animals were 
maintained in a room with a 12-h light/dark cycle and 
a constant temperature (22 ± 2 °C). The day of birth was 
defined as postnatal day 0 (P0). After birth, the litter size 
was adjusted to ten pups per litter to minimise its effect 
on body weight and brain size. All procedures for animal 
care were conducted in accordance with the National 
Institutes of Health Guide for the Care and Use of Labo-
ratory Animals and were approved by the Institutional 
Animal Care and Use Committee at the Seoul National 
University Hospital. Rats were euthanized by decapita-
tion when the experimental procedure was finished.
Chemicals
LPS was purchased from Sigma (St. Louis, MO, USA), 
and enzyme-linked immunosorbent assay (ELISA) 
kits were used for immunoassay of interleukin-1ß (IL-
1ß: MyBioSource, MBS732184) and TNF-α (MyBio-
Source, MBS032310). Monoclonal mouse antibodies 
against O4 (MBS832589) and glial fibrillary acidic pro-
tein (GFAP, IF03L) were purchased from MyBioSource 
(San Diego, CA, USA) and Calbiochem (San Diego, 
CA, USA), respectively. Monoclonal mouse antibody 
to neural-glial antigen 2 (NG2, AB5320) was purchased 
from Millipore (Billerica, MA, USA). Monoclonal rab-
bit antibody to platelet-derived growth factor-α recep-
tor (PDGFα-R, sc-398206) and rabbit antibody to TNF-α 
(sc-52746) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Rabbit antibody to TNF-α 
receptor I (ab19139) and antibody against myelin basic 
protein (MBP, ab-40390) were purchased from abcam 
(Cambridge, UK). Antibody to IL-1ß receptor (NBP1-
32681) was purchased from Novus Biological (Colorado, 
USA). Antibody against Luxol Fast Blue (LFB, LBC-1-
IFU) stain were purchased from ScyTek Laboratories 
(Logan, UT, USA). Ionised calcium-binding adapter mol-
ecule 1 (Iba1, 019-19741) was obtained from FUJIFILM 
Wako Chemicals USA (Irvine, CA, USA). The terminal 
deoxynucleotidyl transferase (TdT)-mediated uridine 
50-triphosphate-biotin nick end labelling (TUNEL) stain-
ing kit was purchased from Millipore (Billerica, MA, 
USA). An enzyme immunoassay (Enbrel ELISA Q-ETA; 
Matriks Biotek Laboratories, Ankara, Turkey) was used 
to quantify the etanercept in cerebral spinal fluid (CSF).
Animal treatment
An intraperitoneal (IP) injection of 2  mg/kg LPS (from 
Escherichia coli, serotype 055: B5) was administered to 
SD rat pups of both sexes on day 3 of life (P3) followed by 
IP injection of etanercept at a dose of 5 mg/kg (LE group) 
or 100 µl of PBS (L group) [15, 16]. The placebo group (P 
group) was injected intraperitoneally with 100 µl of 0.9% 
saline followed by the same volume of PBS (100 µl). The 
room temperature was maintained at 22 ± 2 °C through-
out the experiment. Body weight was measured from 
P3 to P7, and six rats in each group were selected to 
measure body weight beyond P4 and were sacrificed on 
P7. A total of 92 rats from eight litters were used in the 
present study; one pup from each litter was assigned to 
each group. Six rats from each group were sacrificed by 
decapitation on P4 to collect blood and fresh cerebrum 
without olfactory bulb tissue for ELISA assay [16] as well 
as immunohistochemistry and immunofluorescence 
staining. Six rats from each group were sacrificed on P14 
for the evaluation of changes in myelination by immu-
nohistochemistry. A satellite experiment was performed 
to investigate the presence of etanercept in the CSF. 
In one group (LEC group, n = 10), LPS and etanercept 
were given intraperitoneally on P3 as above, and in the 
other group (PC group, n = 10), 100 µl of 0.9% saline and 
etanercept were given on P3. On P4, under light anaes-
thesia with zoletil (2  mg/kg) and isoflurane (1.5%), rat 
pups were placed in a stereotaxic apparatus with a neo-
natal rat adapter, which has light ear pads (David Kopf, 
CA, USA). A small scalp incision was made on the skull 
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surface, and the lambda was exposed and micropipetted 
to obtain 1.5 mm CSF. Then, the CSF was centrifuged at 
3000 rpm for 10 s, and the supernatant was collected for 
analysis.
Determination of IL‑1ß and TNF‑α protein levels in brain 
tissue and blood by ELISA
IL-1ß and TNF-α expression levels were determined by 
ELISA. Cerebrum without olfactory bulb tissues and 
blood from each pup were collected on P4. Samples 
were homogenised by sonication in 1 ml of ice-cold PBS 
(pH 7.2) and centrifuged at 12,000×g for 20 min at 4 °C. 
The supernatant was collected, and the protein concen-
tration was determined using the BCA method. ELISA 
was performed following the manufacturer’s instruc-
tions, and data were acquired using a 96-well plate reader 
(VersaMax, California, USA). The cytokine contents are 
expressed as pg cytokine/mg protein.
Immunohistochemistry and immunofluorescence
Six rats from each group were sacrificed by transcardiac 
perfusion. Immunohistochemical analysis was performed 
on 10-μm tissue sections prepared using a microtome, and 
deparaffinisation and antigen retrieval were conducted. For 
immunohistochemistry staining, primary antibodies were 
used in an antibody dilution buffer in the following dilu-
tions: O4, 1:2000; Iba1, 1:2000; MBP, 1:2000; PDGFα-R, 
1:50; NG2, 1:100 and GFAP, 1:1000. The sections were 
incubated overnight at 4  °C with the primary antibodies 
and then for 2 h with the REAL-HRP system (DaKo REAL 
TM EnVision TM Detection System, CA, USA, Peroxidase/
DAB+, Rabbit/Mouse K5007). Slides were counterstained 
with Dako Mayer’s Hematoxylin Histological Staining 
Reagent. Photomicrographs were captured using a Leica 
DFC 290 microscope with a digital camera system. Immu-
nofluorescence staining was conducted using TUNEL 
assay kits. Next, the sections were incubated overnight 
with anti-O4 antibodies at 4  °C and then incubated with 
a secondary antibody conjugated to a fluorescent probe 
(Alexa Fluor 568, 1:200 anti-mouse IgM, Invitrogen, Grand 
Island, NY, USA) for 2 h in the dark at room temperature. 
Sections were washed with PBS and then mounted using 
VECTASHIELD mounting medium (Vector Laboratories, 
Inc., Burlingame, CA) for visualisation under a fluores-
cence microscope (Leica TCS SP8). The TUNEL-positive 
cells appeared green, and the O4-positive cells appeared 
red. Immunofluorescence staining of GFAP (1:200), Iba-1 
(1:200), TNF-α (1:100), TNF-α receptor (1:100), and IL-1ß 
receptor (1:100) were also conducted as descripted above. 
Secondary antibodies were conjugated to a fluorescent 
probe (Alexa Fluor 488; anti-mouse IgG, 488; anti-rabbit 
IgG, 555; anti-mouse IgG, 594; anti-rabbit IgG, 1:200 Inv-
itrogen, Grand Island, NY, USA). Antigen retrieval and 
the composition of the antibody dilution buffer were con-
ducted according to the manufacturer’s instructions. Stain-
ing intensities were measured in brain cingulum (Bregma 
− 1.00) using Image J software [29].
Statistical analysis
SPSS version 22.0 (SPSS for Windows Inc., Chicago, IL, 
USA) was used for the statistical analysis. Kolmogorov–
Smirnov test was used to evaluate the equality of distribu-
tions and comparison between two groups was performed 
by t-test. ANOVAs with Bonferroni comparison tests were 
used to compare the groups, and the RT-PCR data were 
analyzed by the 2-delta delta  CT method. The results are 
expressed as the mean ± standard deviation.
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